Last reviewed · How we verify
rhGH norditropine simple Xx
rhGH norditropine simple Xx is a Growth hormone Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature in children born small for gestational age.
Recombinant human growth hormone (rhGH) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis.
Recombinant human growth hormone (rhGH) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature in children born small for gestational age.
At a glance
| Generic name | rhGH norditropine simple Xx |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Growth hormone |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
rhGH is a recombinant form of endogenous human growth hormone that activates the growth hormone receptor on target tissues, promoting linear growth in children, increasing lean body mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of its anabolic and growth-promoting effects.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature in children born small for gestational age
- Turner syndrome
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Carpal tunnel syndrome
- Fluid retention
- Arthralgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhGH norditropine simple Xx CI brief — competitive landscape report
- rhGH norditropine simple Xx updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about rhGH norditropine simple Xx
What is rhGH norditropine simple Xx?
How does rhGH norditropine simple Xx work?
What is rhGH norditropine simple Xx used for?
Who makes rhGH norditropine simple Xx?
What drug class is rhGH norditropine simple Xx in?
What development phase is rhGH norditropine simple Xx in?
What are the side effects of rhGH norditropine simple Xx?
What does rhGH norditropine simple Xx target?
Related
- Drug class: All Growth hormone drugs
- Target: All drugs targeting Growth hormone receptor (GHR)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Endocrinology
- Indication: Drugs for Growth hormone deficiency in children
- Indication: Drugs for Growth hormone deficiency in adults
- Indication: Drugs for Short stature in children born small for gestational age
- Compare: rhGH norditropine simple Xx vs similar drugs
- Pricing: rhGH norditropine simple Xx cost, discount & access